Gene transfer and genome editing for familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder.
• It leads to significantly elevated low-density lipoprotein (LDL) cholesterol levels.
• Dysfunctional LDL receptors, primarily in hepatocytes, cause the high LDL levels, accelerating atherosclerosis and increasing mortality risk.

Purpose of the Study:

• To review the pathogenesis of Familial hypercholesterolemia.
• To discuss current and emerging therapeutic strategies.
• To explore the potential of gene therapy for FH and acquired hypercholesterolemia.

Main Methods:

• Literature review of FH pathogenesis.
• Analysis of available treatment options.
• Review of gene therapy strategies under development.

Main Results:

• FH pathogenesis involves dysfunctional LDL receptors leading to severe hypercholesterolemia.
• Current treatments exist, but novel approaches are needed.
• Gene therapy presents promising future therapeutic avenues.

Conclusions:

• Gene therapy offers potential novel treatments for FH.
• These strategies may also be applicable to acquired hypercholesterolemia.
• Further research is needed to evaluate the efficacy and safety of gene therapies.